Gal-3 has the potential to alter the pathogenic course of experimental cerebral malaria (CM) through its binding to the endogenous oligosaccharides on matrix proteins and its release after the lysis of brain-infiltrating macrophages. This evidence concerns the gene LGALS3 and cerebral malaria.